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Abstract
Background: Despite access to effective, safe, and affordable treatment for osteoporosis, at-risk women may choose not to
start bisphosphonate therapy. Understanding the reasons women give for rejecting a clinician’s offer of treatment during
consultations and how clinician’s react to these reasons may help clinicians develop more effective strategies for fracture
prevention and medication adherence.
Methods: We conducted a videographic evaluation of encounters in the Osteoporosis Choice randomized trial of a decision
aid about bisphosphonates vs. usual primary care. Eligible videos involved consultations with women with an estimated 10-
year fragility fracture risk .20% who verbalized at least one reason to not take bisphosphonates. Two reviewers
independently reviewed eligible videos and verbatim transcripts, classifying patient views about bisphosphonate use,
clinicians reponse to those views, and patient adherence at 6 months post visit.
Results: Eighteen video recordings (12 with decision aid) were eligible for analyses. We identified 37 reasons for and against
bisphosphonate therapy. Eleven patients rejected treatment, offering 9 (average of 2 per patient) unique reasons against
initiating bisphosphonates (most common: side effects 39% and distrust of medications in general 33%). When physicians
conceded to patient views the outcome was no bisphosphonate use. Adherence to choices at 6 months was 100%.
Conclusions: The expression of patient preferences is sometimes unfavorable to bisphosphonates treatment even among
well-informed patients at high risk for osteoporotic fractures. At 6 months, patients who expressed concerns about these
medicines behaved consistently with the decision made during the visit.
Citation: Scoville EA, Ponce de Leon Lovaton P, Shah ND, Pencille LJ, Montori VM (2011) Why Do Women Reject Bisphosphonates for Osteoporosis? A
Videographic Study. PLoS ONE 6(4): e18468. doi:10.1371/journal.pone.0018468
Editor: Joseph S. Ross, Yale University School of Medicine, United States of America
Received December 18, 2010; Accepted March 1, 2011; Published April 13, 2011
Copyright:  2011 Scoville et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by the Mayo Clinic Foundation for Medical Education and Research. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kerunit@mayo.edu
Introduction
Bisphosphonates can reduce the risk of osteoporotic fracture in
postmenopausal women [1,2]. Proper use of these agents is
associated with few adverse effects. Generic oral bisphosphonates
have recently become available reducing the cost of treatment.
Despite access to effective, safe, and affordable treatment, many
women at high risk for fractures choose not to initiate therapy,
and, of those who do, up to 50% discontinue treatment in less than
one year [3]. Limited use of bisphosphonates, whether from poor
initiation rates, poor adherence, or high discontinuation, fails to
reduce the risk of osteoporotic fractures which in turn can increase
healthcare costs and greatly decrease quality of life and life
expectancy [4,5,6]. Inadequate treatment remains a key quality
target in the care of patients with osteoporosis.
To understand why women don’t initiate, adhere, or persist
with osteoporosis medications, investigators have surveyed and
discussed preferences with patients [7,8,9]. The most commonly
cited reasons to not initiate bisphosphonate treatment include the
difficult dosing schedule, fear of adverse events, and patient beliefs
that treatment is ineffective and that the condition is not serious
enough to merit treatment [10,11].
To our knowledge, no study has evaluated the reasons patients
express to reject a clinician’s recommendation of bisphosphonate
treatment to prevent osteoporosis fracture during the consultation.
Furthermore, there is no study to evaluate whether the nature of
these reasons changes when women receive structured individu-
alized information about the efficacy, safety and cost of these
medicines during the visit. Also, there is no study to our knowledge
to assess how clinicians respond to the rejections of treatment by
patients.
To uncover these issues, we sought to determine the reasons
women present when expressing hesitation about initiation of
bisphosphonates during primary care consultations with clinicians
and how these clinicians react by studying video recordings of
these consultations. We also sought to determine if these women
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recordings of both usual care visits and of visits in which clinicians
used a tailored decision aid about bisphosphonates in the context
of the Osteoporosis Choice trial (Clinical trials.gov identifier:
NCT00578981).
Methods
Ethics Statement
The Mayo Clinic Institutional Review Board approved all
procedures (IRB ID# 07-003475). Patients and clinicians gave
written informed consent for video recording.
Study Context
This study used video recordings obtained during a randomized
trial of a decision aid (Osteoporosis Choice) versus usual primary
care in 100 postmenopausal women with osteopenia or osteopo-
rosis by bone mineral density. Osteoporosis Choice is a single-
sheet printed decision aid that includes (a) a pictograph showing
the patient’s estimated risk of a major fragility fracture in 10 years
(estimated using the FRAX calculator) [12] and how this risk will
be reduced by using bisphosphonates; (b) a list of adverse effects
and their likelihood; and (c) an estimation of oral bisphosphonates
out-of-pocket costs. Patients were randomly assigned to receive the
decision aid or usual care. Trial procedures included video
recording of visits to assess how information was shared and
discussed in each visit. Patients were recruited from ten academic
primary care sites in and within 60 miles of Rochester, Minnesota,
United States. Eligible patients were postmenopausal women, age
50 and over with osteopenia or osteoporosis, who were not already
taking bisphosphonates or other prescription osteoporosis medi-
cations, who their clinicians found eligible for bisphosphonate
therapy and had a follow-up appointment with that clinician.
Women who could not read English or had, in their clinicians’
judgment, major learning barriers were excluded from this trial.
Details of the methods and main trial results are available
elsewhere [13,14]. The decision aid was found to significantly
improve patient knowledge and involvement in clinical decision
making and to have minimal if any impact on medication
adherence. The Mayo Clinic Foundation for Medical Education
and Research funded this trial. The funding source had no role in
the design, conduct, or decision to publish results of this trial.
Video selection
Two investigators, working independently, reviewed all avail-
able videos from the Osteoporosis Choice trial. Eligible videos for
inclusion in this study were (a) of visits with women at FRAX-
estimated 10-year fragility fracture risk .20%; (b) receiving either
decision aid or usual care; (c) in which the patient verbally
expressed at least one reason against treatment with bisphospho-
nate; (d) regardless of whether the final decision made was to
accept or reject treatment. There were no exclusion criteria.
Data collection
The trial database provided background information about the
patients and clinicians. A professional medical transcriptionist
transcribed the audio channel of the selected videos verbatim.
Two reviewers (ES and PL), working independently, watched
the video recordings and read transcripts for each encounter. Each
reviewer recorded verbatim every reason a patient verbalized for
or against bisphosphonate treatment.
Patients and clinicians reported on the decision to use or not to
use bisphosphonates immediately after the visit; patients reported
ongoing use of bisphosphonates at 6 months post index visit. We
obtained and reviewed pharmacy medication profiles obtained
during the original trial for each patient at 6 months post index
visit.
Data analyses
Before data collection, using the available literature and
discussion among study team members, we determined seven
categories in which to classify patient’s reasons offered for using or
not using bisphosphonates. These categories were against
treatment (a) side effects, (b) distrust of medications, (c) patient
knowledge against treatment, (d) low value of potential benefits, (e)
cost of medication, and in favor of treatment (a) high value of
benefits, (b) patient knowledge in favor of treatment.
We also noted how clinician’s responded to the reasons patients
offered, i.e., by agreeing or disagreeing with the patient or by
presenting new information; and how patients in turn responded,
i.e., by agreeing or disagreeing and pushing for further
deliberation. Based on these observations, we described each
discussion as (a) give-and-take deliberation, (b) physician domi-
nated, or (c) patient dominated. Deliberation took place when
clinicians engaged the patient in conversation by presenting new
information in response to patient’s concerns and expressing
agreement or disagreement with patient views as appropriate.
Patient-dominated responses were those where the clinician
accepted the patient’s opinion regardless of patient’s reasoning
and did not present new information that would contradict patient
views. Clinician-dominated conversations were those where the
clinician insisted on his or her expressed opinion while presenting
little or no new information that would support the patient’s views.
After identifying and categorizing patient and clinician views,
utterances, and reactions, the reviewers met to compare notes and
discuss disagreements.
Results
Only 76 of the 100 enrolled patient visits were video recorded.
Of the high-risk women, 22 had videos in which women made no
statement against using these medicines, leaving 18 eligible videos
(Figure 1). Table 1 summarizes the characteristics of patients
and providers participating in this analysis. Seventeen of the visits
were with physicians and one with a nurse practitioner.
Reviewer agreement
We identified 37 reasons for and against bisphosphonate
therapy: both reviewers independently identified the same 29
(78%) reasons; one reviewer identified 8 additional reasons that
were missed by the other and that – upon discussion and
agreement—were all included for analysis. Four (14%) of the 29
reasons recorded by both reviewers were classified in different
categories; these disagreements were resolved by discussion and
consensus.
Patient views
Seven patients accepted and 11 rejected treatment. Patients
offered 4 unique reasons for and 9 unique reasons against starting
bisphosphonates (Table 2). On average, each patient offered two
reasons for or against therapy regardless of whether they
ultimately accepted or rejected treatment. Figure 2 demonstrates
the complexity of these conversations by illustrating the overlap-
ping nature of patient reasons. Ten of the 11 patients who refused
treatment did not express any positive views about using
bisphosphonates. The use of the decision aid did not appear to
alter patients’ verbalizations of reasons for or against therapy or
the patient’s final decision.
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Most clinicians engaged patients in deliberation about the
option to treat (Table 2). All patient-dominated interactions
resulted in the patient not initiating treatment; there were no
physician-dominated interactions. Patients who expressed a
distrust of all medications in the course of discussion were more
likely to elicit a patient dominated response from their physicians
(4 out of 6 interactions with a patient who expressed generic
distrust of medications were patient dominated).
Deferred response to physician
Three of the four patients who deferred the decision to the
physician or asked the physician for advice ultimately took the
advice. Of these, two physicians recommended starting medica-
tion and two recommended delaying bisphosphonate treatment.
Both patients for whom physicians recommended delaying
treatment chose not to initiate treatment (both were in the
decision aid group). Of the two physicians who recommended
delaying treatment one wished to review records of a previous
bone density but a chart review determined that the physician
never follow up with the patient, while the other physician did
not think the patient warranted treatment at this time and
suggested the patient follow up with a repeat bone scan in one
year.
Decision aid vs. usual care
Patients decided to take treatment in five (42%) discussions in
which the decision aid was used and in two discussion in which it
was not used. The conversations were grossly similar between the
two groups. (Table 3) Notably, all 3 discussions in which patients
expressed placing a high value on the benefits of treatment
occurred in the decision aid group, with none occurring in the
usual care group.
6-month follow up
No patients in this substudy revised their decision within 6
months of the initial consultation. That is, all patients who started
therapy remained on therapy (with perfect adherence as judged by
pharmacy profile review) and no patients who initially declined
therapy started taking bisphosphonates in this period.
Figure 1. Flow diagram for video inclusion.
doi:10.1371/journal.pone.0018468.g001
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All encounters
(N=18)
Accepted treatment
(N=7)
Rejected treatment
(N=11)
Clinicians
Age, mean (SD) 42.7 (10.3) 38.1 (10.2) 45.5 (8.2)
Male, n (%) 12 (67) 3 (43) 9 (82)
Internal Medicine, n (%) 14 (77.8) 6 (85.7) 8 (72.7)
Family Medicine, n (%) 4 (22.2) 1 (24.3) 3 (27.3)
Patients
Age, mean (SD) 70.6 (9.4) 71.7 (25.3) 70.0 (12.3)
Prior fracture, n (%) 12 (67) 5 (71) 7 (64)
Prior bisphosphonate use, n (%) 1 (5) 0 (0) 1 (9)
Estimated 10-year probability of major fragility fractures, mean (SD) 33.8 (18.8) 41.4 (25.3) 28.9 (12.3)
Percentage correct answers on bisphosphonate knowledge, mean (SD) 50.6 (27.0) 62.6 (22.4) 43.1 (30.4)
Identified own 10-year risk of fracture, n (%) 10 (55.6) 3 (43.0) 7 (63.6)
Identified absolute risk reduction in fracture risk with treatment, n (%) 6 (33.3) 2 (29.0) 4 (36.4)
doi:10.1371/journal.pone.0018468.t001
Table 2. Frequency of patient verbalizations for and against bisphosphonate treatment as well as physician response style in
relation to acceptance or rejection of treatment.
Total, n (%)
Accept treatment,
n( % )
Reject treatment,
n (%) Representative quote
A. Verbalized against treatment
1. Concern about side effects 7 (39) 5 (71) 2 (18) ‘‘The jaw thing frightens me.’’
2. Distrust of medications 6 (33) 0 (0) 6 (55) ‘‘I won’t take pills so don’t ask.’’
3. Patient knowledge against treatment
a. Family member with no osteoporosis
complication
3 (17) 0 (0) 3 (27) ‘‘My mother was 96 before she broke a
bone.’’
b. History of adverse effect
(personal or other)
3 (17) 2 (29) 1 (9) ‘‘I think my mother took this and it made her
legs and feet swell’’
c. Health good without other treatments 1 (6) 0 (0) 1 (9) ‘‘In general my health’s pretty darn good
overall, so why mess with a good thing?’’
4. Low value of potential benefits
a. Too old to benefit 3 (17) 1 (14) 2 (18) ‘‘I don’t want to live that long’’
b. Limited knowledge of osteoporosis 2 (11) 0 (0) 2 (18) ‘‘If I felt bad…[I would consider treatment]’’
c. Medications will not produce benefit 2 (11) 1 (14) 1 (9) ‘‘It won’t make it get better?’’
5. Cost of medication 2 (11) 1 (14) 1 (9) ‘‘If it’s not too expensive.’’
B. Verbalized in favor of treatment
1. High value of benefits 3 (17) 2 (29) 1 (9) ‘‘Ok, because I don’t want to go back to a
nursing home’’
2. Patient knowledge in favor of treatment
a. Family member with poor outcome 3 (17) 3 (43) 0 (0) ‘‘My mother fell and broke her hip. That was
the end of it’’
b. Personal research and insight 2 (11) 2 (29) 0 (0)
C. Conversation Style
Patient dominated 4 (22) 0 (0) 4 (36)
Patient-clinician deliberation 14 (78) 7 (100) 7 (64)
Physician dominated 0 (0) 0 (0) 0 (0)
doi:10.1371/journal.pone.0018468.t002
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Our findings
We found high-risk patients who expressed treatment prefer-
ences to their clinician that were unfavorable to bisphosphonate
therapy. Patients with only such preferences were more likely to
leave the visit rejecting therapy than those who expressed at least
one reason to take treatment. The most common reasons
expressed were a concern about side effects (39%) or a distrust
of medications in general (33%). Patients included in this analysis,
all of whom were able to express a reason against bisphosphonates
and discuss it with their clinician, adhered to their decision (to take
or not to take bisphosphonates) for at least 6 months post visit.
Limitations and strengths of this study
Feweligible videos– i.e., videos of women at high riskfor fracture
stating at least one reason to not take treatment – were available for
review. Although small, our sample was representative of the whole
of the Osteoporosis Choice trial population in age, socioeconomic
status,and previousmedication use. Oursample has a higherrate of
previous fracture and 10-year risk of major fragility fracture as we
purposefully selected high-risk women. While fit to our purpose of
identifying expressions that factor into patient’s decision to reject
bisphosphonate therapy, this study does not offer the depth of more
complex communication analyses or qualitative attempts to identify
the underlying framework of treatment refusal. Also, we did not
include videosofwomen expressing nonverballytheir preference for
osteoporosis treatment.
Due to the difficulty of blinding reviewers to the outcome of the
encounter as it was often expressed through the course of the video
recording, we tried to limit bias by having duplicate independent
review. While we had a 78% initial agreement and 100%
agreement by consensus, this may not have been sufficient to
prevent error in categorization. Our videographic analysis looked
at only one discussion of bisphosphonate therapy. While none of
our patients altered their treatment through the course of 6
months of follow up, it is impossible to know how many of these
decisions may have been revisited after that period. The
population studied had adequate access to primary and specialty
care, and to prescription drug coverage. Therefore, their
preferences may not apply to women with limited health care
access and literacy.
Table 3. Frequency of patient verbalizations for and against
bisphosphonate treatment as well as physician response style
in relation to decision aid or control group.
Decision Aid,
n( % )
Control,
n( % )
A. Verbalized Against Treatment
1. Concern about side effects 5(42) 2(33)
2. Distrust of medications 3(25) 3(50)
3. Patient knowledge against treatment 5(42) 2(33)
4. Low value of potential benefits 5(42) 2(33)
5. Cost of medication 1(8) 1(17)
B. Verbalized Pro Treatment
1. High value of benefits 3(25) 0(0)
2. Patient knowledge in favor of
treatment
4(33) 1(17)
Conversation Style
Patient dominated 1(8) 3(50)
Patient-Clinician deliberation 11(92) 3(50)
Physician dominated 0(0) 0(0)
doi:10.1371/journal.pone.0018468.t003
Figure 2. Reasons to take or not take bisphosphonates. Most women gave multiple reasons for and against bisphosphonate therapy. This
figure represents the overlap of multiple reasons presented during a single visit for patients who A) accepted treatment and B) rejected therapy.
doi:10.1371/journal.pone.0018468.g002
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of the goal of the sub-study; we did not rely on post visit recall to
determine the reasons women had for taking or not bisphospho-
nates; two reviewers working independently assessed the encoun-
ters using pre-defined categories; and for at least 12 of the 18
videos, the preferences expressed should be considered informed
as these patients had just reviewed an effective decision aid with
their clinician.
Comparison with other studies
Many of the reasons that women verbalized to their clinicians
for not desiring bisphosphonate treatment are similar to those
elicited in surveys including a distrust of all medications and
concerns of side effects [10,11]. Prior investigations used surveys
not directly linked to a particular visit, and usual care visits seldom
succeed in informing women about the pros and cons of therapies
in a tailored way. To this extent, our study overcomes these
limitations and further indicates that these patients sometimes
express these preferences directly to their clinicians.
Implications for practice, policy, and further research
Policy discussions have increasingly endorsed the notion that
shared-decision making can improve the appropriateness and
efficiency of health care delivery. This videographic evaluation
suggests that shared-decision making may provide a means by
which to identify women at high risk of osteoporotic fractures whose
preferences may not align with evidence-based practice guidelines.
By identifying these women, clinicians may be able to tailor
regimens to align with their preferences, thus, reducing non-
adherence (to programs women do not want to follow) and
improving healthcare value. Although our study does not provide
direct evidence of this, the kind of reasons women in this substudy
offered would logically reject a common solution proposed to the
problemofnonadherenceto weeklyoralbisphosohonates:the useof
less frequently administered oral or intravenous bisphosphonates.
By virtue of their rejection of bisphosphonates, women may
force practitioners to become more proficient at recommending
nonpharmacological means of reducing the burden of osteoporotic
fractures in these high risk women. Such regimens may include
measures to improve posture, fitness and balance, reduce visual,
mechanical and propioceptual limitations, and prevent falls. The
extent of this proficiency and of the necessary resources to support
the implementation of these regimens remains unclear.
Conclusions
The expression of patient values to the clinician is sometimes
unfavorable to bisphosphonate therapy even in women at high risk
of osteoporotic fracture. Patients who express only values
unfavorable to bisphosphonate therapy are more likely to leave
the visit rejecting therapy than those who express at least one value
favorable to treatment. Patients who discussed at least one concern
about these medicines were adherent to their decision to take or
not bisphosphonates 6 months post visit. Patient-centered
osteoporosis care to reach at-risk women may require a change
in priority from drug programs (e.g., changing formulation,
generics) to nonpharmacological strategies (e.g., fall prevention).
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